In silico and in vitro inhibition of host-based viral entry targets and cytokine storm in COVID-19 by ginsenoside compound K

Heliyon, Journal Year: 2023, Volume and Issue: 9(9), P. e19341 - e19341

Published: Aug. 20, 2023

SARS-CoV-2 is a novel coronavirus that emerged as an epidemic, causing respiratory disease with multiple severe symptoms and deadly consequences. ACE-2 TMPRSS2 play crucial synergistic roles in the membrane fusion viral entry of (COVID-19). The spike (S) protein binds to receptor for entry, while proteolytically cleaves S into S1 S2 subunits, promoting fusion. Therefore, are potential drug targets treating COVID-19, their inhibition promising strategy treatment prevention. This study proposes ginsenoside compound K (G-CK), triterpenoid saponin abundant Panax Ginseng, dietary medicinal herb highly consumed Korea China, effectively inhibits expression. We initially conducted in-silico evaluation where G-CK showed high affinity binding sites two target proteins SARS-CoV-2. Additionally, we evaluated stability using molecular dynamics (MD) simulations 100 ns, followed by MM-PBSA calculations. MD free energy calculations revealed has stable favorable energies, leading strong targets. Furthermore, suppressed ACE2 mRNA expression A549, Caco-2, MCF7 cells at concentration 12.5 μg/mL LPS-induced RAW 264.7 6.5 μg/mL, without significant cytotoxicity.ACE2 were significantly lower A549 following treatment. These findings suggest may evolve therapeutic against COVID-19.

Language: Английский

---

Chemical Constituents of Parsley (Petroselinum crispum) Leaf Extract and Its Potential in Mitigating the Effects of Viral Infections

ACS Food Science & Technology, Journal Year: 2023, Volume and Issue: 3(12), P. 2108 - 2116

Published: Nov. 29, 2023

The pathogenesis of coronavirus disease 2019 (COVID-19) is facilitated by the binding severe acute respiratory syndrome 2 (SARS-CoV-2) spike protein to angiotensin-converting enzyme (ACE2) in a host; hence, interfering with interaction between SARS-CoV-2's and ACE2 could possibly reduce risk COVID-19. This study aimed analyze chemical compositions evaluate antiviral free radical scavenging effects parsley leaf extracts. Twenty-two compounds were tentatively identified, octadecenamide being reported for first time parsley. Parsley extract was able inhibit SARS-CoV-2-ACE2 70% at concentration 3.3 mg dry parsley/mL activity 86% 5.0 mg/mL. showed capacity against HO•, DPPH•, ABTS•+ values 184.09, 0.03, 9.58 μmol Trolox equivalent/gram, respectively. Findings from this suggest parsley's potential ability mitigate risks symptoms

Language: Английский

---

Potential of Clove, Cinnamon and Honeysuckle in Suppressing the SARS-CoV-2 Spike Protein-ACE2 Binding, Inhibiting ACE2 Activity, and Scavenging Radicals

Journal of Food Bioactives, Journal Year: 2024, Volume and Issue: unknown, P. 52 - 60

Published: June 1, 2024

Water and ethanol extracts of clove (Syzygium aromaticum (L.) Merr. & L.), cinnamon (Cinnamomum verum) honeysuckle (Lonicerae japonicae) were examined for their chemical compositions, inhibition SARS-CoV-2 spike protein-ACE2 binding, ACE2 inhibition, free radical scavenging activity. UHPLC-MS/MS analysis tentatively identified 34, 36, 27 compounds in clove, honeysuckle, water (WE) (EE), respectively. The dose-dependently suppressed binding activity Clove WEs at 33.3 mg dry botanical equivalents (BE)/mL, EEs 3.3 BE/mL showed almost 100% S-protein-ACE2 TPC values ranged from 5.3 GAE/g (honeysuckle EE) to 180.0 (clove EE). highest HO·, DPPH·, ABTS·+ 2181 EE), 536.91 WE), 3525.1 WE) µmol TE/g These data suggested the potential these botanicals reducing risk infection COVID-19 severe symptom development.

Language: Английский

---

COVID 19: Prevention and treatment through the Indian perspective

Cytokine, Journal Year: 2024, Volume and Issue: 183, P. 156756 - 156756

Published: Sept. 15, 2024

Language: Английский

---

Application and mechanism of natural products and nutrient elements in COVID-19

Journal of Functional Foods, Journal Year: 2024, Volume and Issue: 123, P. 106561 - 106561

Published: Nov. 17, 2024

Language: Английский

---

Contribution of traditional Japanese Kampo medicines, kakkonto with shosaikotokakikyosekko, in treating patients with mild-to-moderate coronavirus disease 2019: Further analysis of a multicenter, randomized controlled trial

Journal of Infection and Chemotherapy, Journal Year: 2023, Volume and Issue: 29(11), P. 1054 - 1060

Published: July 26, 2023

We previously reported the finding of symptom relief in a randomized controlled trial with combined use kakkonto and shosaikotokakikyosekko added to conventional treatment patients coronavirus disease 2019 (COVID-19). For further evaluation, we performed post hoc analysis focused on disappearance without recurrence, determine clearer effect Kampo medicine. Patients mild moderate COVID-19 were randomly allocated control group receiving symptomatic therapy or (2.5 g) three times daily addition therapy. The data 161 (Kampo group, n = 81; 80) analyzed for time disappearance. Kaplan-Meier Cox proportional hazard estimates symptoms showed that all each targeted this study disappeared faster than although not statistically significant (all cases; ratio [HR] 3.73, 95% confidence interval [CI] 0.46-29.98, log-rank p 0.1763). In supplemental assessment using covariate adjustment competing risk analysis, fever cases, HR 1.62, CI 0.99-2.64, 0.0557; unvaccinated 1.68, 1.00-2.83, 0.0498) shortness breath significantly 1.92, 1.07-3.42, 0.0278; 2.15, 1.17-3.96, 0.0141). These results demonstrate advantages acute COVID-19.

Language: Английский

---